EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Proposal for a Biologic Staging System of Parkinson’s Disease

Lana M Chahine, Kalpana Merchant, Andrew Siderowf, Todd Sherer, Caroline Tanner, Kenneth Marek, Tanya Simuni

Journal of Parkinson’s Disease · 2023

DOI: 10.3233/jpd-225111 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Parkinson’s Disease, 2023. Verfasst von Lana M Chahine und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, University of Pittsburgh, Pittsburgh, PA, USA. Hauptthemen laut MEDLINE: Parkinson Disease, Lewy Body Disease, Biological Products. Die Arbeit wurde bisher 79-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Parkinson’s disease (PD) research field has seen the advent of several promising biomarkers and a deeper understanding of the clinical features of the disease from the earliest stages of pathology to manifest disease. Despite progress, a biologically based PD staging system does not exist. Such staging would be a useful framework within which to model the disease, develop and validate biomarkers, guide therapeutic development, and inform clinical trials design. We propose that the presence of aggregated neuronal α-synuclein, dopaminergic neuron dysfunction/degeneration, and clinical signs and symptoms identifies a group of individuals that have Lewy body pathology, which in early stages manifests with what is now referred to as prodromal non-motor features and later stages with the manifestations of PD and related Lewy body diseases as defined by clinical diagnostic criteria. Based on the state of the field, we herein propose a definition and staging of PD based on biology. We present the biologic basis for such a staging system and review key assumptions and evidence that support the proposed approach. We identify gaps in knowledge and delineate crucial research priorities that will inform the ultimate integrated biologic staging system for PD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parkinson DiseaseLewy Body DiseaseBiological ProductsHumansalpha-SynucleinLewy BodiesNerve DegenerationBiomarkersProdromal Symptoms

Stichwörter der Autor:innen

Parkinson’s diseasealpha-synucleinbiomarkersdisease staging

Substanzen

alpha-SynucleinBiomarkersBiological Products

Autor:innen und Institutionen

  • Department of Neurology, University of Pittsburgh, Pittsburgh, PA, USA.
  • Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
  • Department of Neurology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
  • The Michael J Fox Foundation for Parkinson's Research, New York, NY, USA.
  • Department of Neurology, Weill Institute for Neurosciences, University of San Francisco, San Francisco, CA, USA.
  • Institute for Neurodegeneration, New Haven, CT, USA.

Zitieren

APA

Chahine, L. M., Merchant, K., Siderowf, A., Sherer, T., Tanner, C., Marek, K., & Simuni, T. (2023). Proposal for a Biologic Staging System of Parkinson’s Disease. Journal of Parkinson’s Disease. https://doi.org/10.3233/jpd-225111

Vancouver

Chahine LM, Merchant K, Siderowf A, Sherer T, Tanner C, Marek K, et al. Proposal for a Biologic Staging System of Parkinson’s Disease. Journal of Parkinson’s Disease. 2023. doi:10.3233/jpd-225111

BibTeX
@article{Chahine2023,
  author = {Chahine, Lana M and Merchant, Kalpana and Siderowf, Andrew and Sherer, Todd and Tanner, Caroline and Marek, Kenneth and Simuni, Tanya},
  title = {Proposal for a Biologic Staging System of Parkinson’s Disease},
  journal = {Journal of Parkinson’s Disease},
  year = {2023},
  doi = {10.3233/jpd-225111}
}
Kostenlos starten →